Status:
NO_LONGER_AVAILABLE
Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
Lead Sponsor:
Celltex Therapeutics Corporation
Conditions:
Alzheimer Disease
Brief Summary
This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated...
Eligibility Criteria
Inclusion
- The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability.
- All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined
- Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy.
Exclusion
- Current diagnosis of malignancy
- Renal/liver dysfunction: Exceed two times as normal subject
- Pregnant or nursing
- Received other trial drugs within 30 days after participation of this study
- Experienced major surgery or trauma in the last 14 days
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04855955
Last Update
February 7 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.